carmofur has been researched along with Bladder Cancer in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil (5-FU), in preventing postoperative recurrence of bladder cancer, a randomized controlled study with 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) as the reference standard was performed." | 9.05 | [A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer]. ( Hisazumi, H; Kanda, S; Katsumi, T; Kawaguchi, K; Mikawa, I; Misaki, T; Miyagi, T; Nakamura, T; Orito, M; Sakai, A, 1985) |
| "This study was carried out to evaluate the effects of carmofur (Mifurol), a masked compound of 5-fluorouracil (5-FU), in preventing postoperative recurrence of urogenital carcinoma (especially in bladder cancer)." | 7.67 | [Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent]. ( Funai, K; Hayahara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Nishio, S; Yasumoto, R; Yuki, K, 1987) |
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 5.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| "To evaluate the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil (5-FU), in preventing postoperative recurrence of bladder cancer, a randomized controlled study with 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) as the reference standard was performed." | 5.05 | [A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer]. ( Hisazumi, H; Kanda, S; Katsumi, T; Kawaguchi, K; Mikawa, I; Misaki, T; Miyagi, T; Nakamura, T; Orito, M; Sakai, A, 1985) |
| "This study was carried out to evaluate the effects of carmofur (Mifurol), a masked compound of 5-fluorouracil (5-FU), in preventing postoperative recurrence of urogenital carcinoma (especially in bladder cancer)." | 3.67 | [Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent]. ( Funai, K; Hayahara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Nishio, S; Yasumoto, R; Yuki, K, 1987) |
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 1.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| "In groups 1, 2 and 3, urinary bladder tumors developed in 13 of 18, 0 of 20, and 4 of 19, respectively." | 1.27 | Effect of 1-hexylcarbamoyl-5-fluorouracil on development of rat urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Hirao, Y; Iwata, H; Matsuki, H; Okajima, E; Ozono, S; Sasaki, K; Takahashi, S; Tsunemi, K, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wada, S | 1 |
| Yasumoto, R | 2 |
| Kashihara, N | 1 |
| Kishimoto, T | 2 |
| Maekawa, M | 2 |
| Hayahara, N | 2 |
| Kawakita, J | 2 |
| Nishijima, T | 2 |
| Morikawa, Y | 2 |
| Horii, A | 1 |
| Ozono, S | 1 |
| Iwata, H | 1 |
| Tsunemi, K | 1 |
| Takahashi, S | 1 |
| Matsuki, H | 1 |
| Sasaki, K | 1 |
| Hirao, Y | 1 |
| Okajima, E | 1 |
| Nishio, S | 1 |
| Funai, K | 1 |
| Yuki, K | 1 |
| Ueda, K | 1 |
| Jinno, H | 1 |
| Watanabe, H | 1 |
| Ohtaguro, K | 1 |
| Misaki, T | 1 |
| Hisazumi, H | 1 |
| Sakai, A | 1 |
| Nakamura, T | 1 |
| Kanda, S | 1 |
| Mikawa, I | 1 |
| Miyagi, T | 1 |
| Katsumi, T | 1 |
| Orito, M | 1 |
| Kawaguchi, K | 1 |
1 trial available for carmofur and Bladder Cancer
| Article | Year |
|---|---|
[A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Administrat | 1985 |
4 other studies available for carmofur and Bladder Cancer
| Article | Year |
|---|---|
[Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1992 |
Effect of 1-hexylcarbamoyl-5-fluorouracil on development of rat urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Antineoplastic Agents; Body Weight; Butylhydroxybutylnitrosamine; Fluorouracil; Male; Nitro | 1988 |
[Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Thera | 1987 |
[Combination effects of CDDP, ACR and HCFU on progressive urothelial tumors].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administra | 1985 |